We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FTC is suing Barr Laboratories and Warner Chilcott, seeking to nullify a $20 million agreement to keep a generic version of Warner’s contraceptive Ovcon-35 off the market — a move that shows the FTC is taking a stronger stance against what it sees as anticompetitive deals within the drug industry, one analyst says.
The FTC plans to investigate the competitive effects that authorized generics are having on the drug industry, yet another sign that the agency is taking a harder line against potentially anticompetitive deals between drugmakers.
The FTC plans to investigate the competitive effects that authorized generics are having on the drug industry, yet another sign that the agency is taking a harder line against potentially anticompetitive deals between drugmakers.
The FTC is suing Barr Laboratories and Warner Chilcott, seeking to nullify a $20 million agreement to keep a generic version of Warner's contraceptive Ovcon-35 off the market -- a move that shows the FTC is taking a stronger stance against what it sees as anticompetitive deals within the drug industry, one analyst says.
Teva Pharmaceutical and Ivax will probably not have to sell off many products to consummate their pending merger, a Standard & Poor’s analyst said, despite an FTC request for more information about the proposed deal.
The lure of authorized generics (AGs) has caused some generics makers to jump ship and forge partnerships with brand firms, but regardless of generic drugmaker support, AG deals may start to face more FTC scrutiny over their long-term anti-competitive effects, industry experts said at the recent Institute for International Research’s annual Generic Drugs Summit.
The Federal Trade Commission (FTC) has tentatively approved Novartis’ acquisition of U.S. generic firm Eon Labs on the condition that Novartis sells three drug products to a competitor.
Novartis has agreed to sell products in three European countries to gain final European Union (EU) approval for its planned merger of German generic drugmaker Hexal AG and Hexal’s U.S. sister company Eon Labs, the European Commission (EC) announced May 27.
The FTC is weighing the merits of conducting a study on the competitive effects of authorized generics, but it is looking for input from drugmakers before deciding how to proceed on the matter, an agency official told a recent industry conference.